Methyl-prednisolone pulses in COVID-19 pneumonia (COV2-MIIHUC)

Study identification

• EU PAS number:
  EUPAS36287
• Study ID:
  36288
• Official title and acronym:
  Methyl-prednisolone pulses in COVID-19 pneumonia (COV2-MIIHUC)
• DARWIN EU® study:
  No
• Study countries:
  Spain
• Study description:
  We conducted an observational study using data collected from routine care to compare the clinical course of patients with COVID-19 pneumonia receiving week 2 methyl-prednisolone pulses (week-2-MP), 125-250 mg/d for 3 consecutive days with no subsequent tapering with standard of care. Time to death and time to death or endotracheal intubation were the outcome variables. Additional clinical and therapeutic variables were used to fit multivariate Cox proportional risk models.
• Study status:
  Finalised

Research institutions and networks

Institutions

Biocruces Bizkaia

Study timelines

Date when funding contract was signed

Planned:24/04/2020

Actual:24/04/2020

Study start date

Planned:01/05/2020

Actual:01/05/2020

Data analysis start date

Planned:08/06/2020

Actual:08/06/2020

Date of final study report

Planned:10/07/2020

Actual:10/07/2020

Sources of funding

Other

More details on funding

Biocruces Bizkaia

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable

Other study registration identification numbers and links

Basque Country Research Ethics Committee (code EPA2020032)